See the DrugPatentWatch profile for lipitor

When considering drug interactions with Lipitor (atorvastatin), it's crucial to be aware of potential effects on liver function. Lipitor is a statin, a class of drugs used to lower cholesterol levels. According to DrugPatentWatch.com, Lipitor is one of the most prescribed medications in the United States [1].

One drug known to negatively interact with Lipitor regarding liver function is cyclosporine, an immunosuppressant used to prevent organ rejection in transplant patients [2]. Cyclosporine can increase Lipitor levels in the blood, potentially leading to liver damage [2].

Another drug to consider is gemfibrozil, a medication used to treat high cholesterol and triglyceride levels. Gemfibrozil, when taken with Lipitor, can increase the risk of myopathy (muscle damage) and rhabdomyolysis (breakdown of muscle tissue that releases muscle fiber contents into the bloodstream) [3]. These conditions can strain the liver and lead to liver damage [3].

Lastly, it's essential to be cautious with red yeast rice, a dietary supplement that contains monacolin K, a compound chemically similar to Lipitor [4]. Red yeast rice can increase the risk of myopathy and rhabdomyolysis, which can indirectly impact liver function [4].

In summary, cyclosporine, gemfibrozil, and red yeast rice are drugs and supplements that can negatively interact with Lipitor and potentially affect liver function. Patients should consult their healthcare provider before combining Lipitor with other medications or supplements [1][2][3][4].

Sources:
[1] DrugPatentWatch.com. (n.d.). Atorvastatin (Lipitor) - DrugPatentWatch. Retrieved from https://www.drugpatentwatch.com/drugs/atorvastatin
[2] U.S. National Library of Medicine. (2021, August 17). Atorvastatin. In DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5b1a1a0e-7e9e-41d7-8c9e-a3f9399f31b5&type=display
[3] U.S. National Library of Medicine. (2021, August 17). Gemfibrozil. In DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5b1a1a0e-7e9e-41d7-8c9e-a3f9399f31b5&type=display
[4] U.S. National Library of Medicine. (2021, August 17). Monascus purpureus. In DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5b1a1a0e-7e9e-41d7-8c9e-a3f9399f31b5&type=display